No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Elite Medical Experts Weighs in on Philips’ Recall of Breathing Machines That May Emit Toxins

Editor: What To Know

  • FDA warned that degraded PE-PUR, a component of the foam used to dampen noise and vibration, may inadvertently enter the device’s airflow pathway where it can be inhaled or ingested during therapeutic use of the machine.
  • Food and Drug Administration (FDA) alerted the public about a voluntary recall of specific Philips Respironics ventilators, BiPAP, and CPAP devices due to the risk of exposing users to particulate matter and off-gassing from polyester-based polyurethane (PE-PUR).
  • “Inhalation of particulate foam can lead to difficulty breathing and frank respiratory failure, and bacteria or fungus carried into the body can cause infection in the respiratory tract and lungs.

On June 30, 2021, the U.S. Food and Drug Administration (FDA) alerted the public about a voluntary recall of specific Philips Respironics ventilators, BiPAP, and CPAP devices due to the risk of exposing users to particulate matter and off-gassing from polyester-based polyurethane (PE-PUR).

FDA warned that degraded PE-PUR, a component of the foam used to dampen noise and vibration, may inadvertently enter the device’s airflow pathway where it can be inhaled or ingested during therapeutic use of the machine. The recall notice followed Philips’ April 2021 announcement that they had internally “identified a quality issue in a component that is used in certain sleep and respiratory care products.”

“Direct exposure to foam particulates and chemicals can be dangerous for several reasons,” said Dr. Venktesh Ramnath, an Associate Clinical Professor of Pulmonary Medicine at UC San Diego Health. “Inhalation of particulate foam can lead to difficulty breathing and frank respiratory failure, and bacteria or fungus carried into the body can cause infection in the respiratory tract and lungs.” Regarding off-gassing, Dr. Ramnath added, “inhalation of isocyanates and other gases associated with polyurethane can cause lung irritation, and some may be carcinogenic in their own right. Prolonged exposure to these chemicals is worrisome, particularly since many people using CPAP and BiPAP already have underlying asthma and other respiratory diseases.”

“The complex issues in this recall will necessitate expert witnesses from a variety of disciplines,” says Dr. Burton Bentley II, an Emergency Medicine specialist and CEO of Elite Medical Experts. “We anticipate the need for experts in Pulmonology, Toxicology, Epidemiology, Biomedical Device Engineering, and Polymer Science. Physician experts in Occupational & Environmental Medicine will also have a role since they are frequently involved in human exposure to toxic compounds.” Regardless of the trajectory of litigation, Dr. Bentley added, “the most important thing right now is to focus on the health and safety of the millions of people affected by the recall. That means seeing a doctor and assuring that you have a safe device.”

Full article can be found here.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy